The implications of statin induced peripheral neuropathy

West, Brenton

doi:10.1186/1757-1146-4-s1-p57

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings were consistent with our previous knowledge regarding the probability of peripheral neuropathy following drug consumption (axonal neuropathy) ( 1 , 20 , 21 ). Brenton West found that the prevalence of this type of neuropathy was 4–14 times higher among patients using statins ( 22 ) Gaist stated that patients on statins are 2.5 times more susceptible to polyneuropathy in comparison with the normal population ( 23 ). In a prospective study with electrodiagnostic follow-up, Pavel Otruba evaluated the peripheral nerves of the lower limbs among 42 patients with hyperlipidemia at the beginning of the statin consumption period and then at the 6 th , 12 th and 24 th month, using the NCS criteria (tibial, peroneal, sural and superficial peroneal nerve features); at the end, they only found significant differences in the nerve conduction latency of the F wave for motor nerves, and concluded that “long-term use of statins could make visible changes in electrophysiological findings; however, these probable changes are clinically silent” ( 12 ).…”

Section: Discussionmentioning

confidence: 99%

Lipid-lowering drugs (statins) and peripheral neuropathy

et al. 2018

View full text Add to dashboard Cite

Background and aimPeripheral neuropathy is a disorder with often unknown causes. Some drugs, including statins, are proposed to be among the causes of peripheral neuropathy. This study aimed at evaluating this condition by electrodiagnostic study among patients who had received statins.MethodsThis case-control study was conducted in Shiraz, Iran in 2015, and included 39 patients aged 35–55 who had received statins for at least 6 months, and 39 healthy matched controls. Using electrodiagnosis, the sensory and motor wave features (amplitude, latency and nerve conduction velocity) of the peripheral nerves (Median, Ulnar, Tibial, Sural, and Peroneal) were evaluated among the subjects. Data were analyzed using SPSS software and p<0.05 was considered statistically significant.ResultsRegarding the occurrence of neuropathy, there were no significant differences in any of the definitions presented for peripheral neuropathy. However, the difference was close to significance for one definition [2 abnormalities in 2 nerves (p=0.055)]. Regarding mean values of the features, significant differences were observed in two features: amplitude of the peroneal motor nerve (p=0.048) and amplitude of the sural sensory nerve (p=0.036).ConclusionSince statins are widely used, awareness regarding their side-effects would lead to better treatment. Even though no significant differences were found between the groups regarding the occurrence of peripheral neuropathy, there were significant differences in amplitudes of the sural sensory response and the peroneal motor response. This indicates the involvement of peripheral nerves. Therefore, we recommend that patients and physicians should be informed about the possible symptoms of this condition.

show abstract

Section: Discussionmentioning

confidence: 99%

Lipid-lowering drugs (statins) and peripheral neuropathy

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Although it is a well-known complication of diabetes mellitus, cases of neuropathy among non-diabetic statin users have also been reported but research on the same is limited [48]. A proposed mechanism explains that interrupted cholesterol synthesis leads to its deficit in the neuronal cell membranes, causing nerve damage [49].…”

Section: Neuropathymentioning

confidence: 99%

Statin use and safety concerns: an overview of the past, present, and the future

Mulchandani

Lyngdoh

Kakkar

2020

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Introduction: Dyslipidemia is a significant risk factor for cardiovascular disorders and contributes to significant morbidity and mortality associated with CAD and stroke worldwide. Statins are the most commonly prescribed drugs for the prevention and management of dyslipidemia globally. Although they provide immense therapeutic benefit, they are associated with clinically significant adverse effects, predominantly muscle, nerve, liver, and cognition-related besides new-onset diabetes. This has sparked various controversies, bringing to the fore, ambiguities that continue to exist in the scientific evidence, in relation to statin-associated harms. Therefore, it becomes essential to have a better understanding of safety issues related to statin use in various populations.Areas covered: This review describes the most common adverse effects of statins, examines available evidence and highlights the role of ethnicity, lipophilicity and other biological factors that could mediate and/or influence the relationship. MEDLINE was searched via PubMed to obtain relevant articles on dyslipidemia and statin safety. Expert opinion: The effectiveness of statins is presently unmatched. Further research is warranted to gain insights into the diverse pharmacological effects of statins in various population subgroups. This would assist prescribers in making better informed decisions. Specific treatment strategies for vulnerable groups can significantly attenuate harms, improve risk-benefit ratios, and ultimately enhance patient experience.

show abstract